Association between Visual Acuity and Medical and Non-Medical Costs in Patients with Wet Age-Related Macular Degeneration in France, Germany and Italy
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Introduction Exudative ('wet') age-related macular degeneration (ARMD) is the major cause of blindness in Western developed countries. Treatments aimed at preserving vision are already available and new compounds are under development. Micro-economics information will be pivotal to justifying forthcoming investment.Objective This study sought to investigate the costs of exudative ARMD in patients who were actively treated at ophthalmology referral centres in three European countries: France, Germany and Italy.Method This cross-sectional observational study was conducted in France, Germany and Italy in 2004. The following data were collected: ARMD description, visual acuity (VA), and the medical and non-medical resources used for ARMD in the preceding year. The economic perspective was that of society. ANOVA for cost variables estimated the impact of ARMD per eye, adjusted for sex and age. Both hospital and ambulatory eye centres were included. Patients with exudative ARMD were stratified into four levels of severity using VA thresholds of 20/200 for the worst eye (WE) and 20/40 for the best eye (BE). The main outcome measure was medical and non-medical costs.Results 360 patients were included (females 60%; mean age 77 years; mean interval since diagnosis 2.3 years). The two groups with the greatest difference in severity of VA loss consisted of BE >or= 20/40, WE >or= 20/200 (27.2% of patients) and BE <20/40, WE <20/200 (25.5% of patients). Total cost was two-thirds medical and one-third non-medical. Total costs increased with ARMD severity and were 1.1-2 times greater for severe disease compared with less severe disease. Average medical costs (2004 values) in France were euro 3714, compared with euro 1810 in Germany and euro 2020 in Italy, and showed slight increases with ARMD severity. Non-medical costs were significantly higher for patients with severe disease and highest in Germany.Conclusion The impact of ARMD on costs was considerable and a positive correlation was found between total costs and ARMD severity. Differences among countries were partly explained by differences in customary care delivery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While annual direct non-medical costs were uniformly lower than direct medical costs in three studies [34, 39, 40] reporting both types of costs, they were higher in other cases [37, 41–43, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [42]
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [42]
In the citing paper
“Often, direct non-medical costs increased in line with the severity of vision impairment [37, 41, 42, 45] and in certain instances exceeded direct medical costs in patients with more severe vision impairment [42, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [42]
In the citing paper
“For instance, two multi-country studies recorded direct non-medical costs that were higher than direct medical costs in Germany [41, 42] as opposed to other countries.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [42]
In the citing paper
“Often, direct non-medical costs increased in line with the severity of vision impairment [37, 41, 42, 45] and in certain instances exceeded direct medical costs in patients with more severe vision impairment [42, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [42]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Leibowitz, H. M., Krueger, D. E., Maunder, L. R., Milton, R. C., KINI, M. M., Kahn, H. A., Nickerson, R. J., Pool, J., Colton, T., Ganley, J. P., et al. (1980) · PubMed · Cited by 1,250
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Risk factors for age-related macular degeneration
Smith, W., Assink, J., Klein, R., Mitchell, P., Klaver, C. C. W., Klein, B. E. K., Hofman, A., Jensen, S., Wang, J. J., & de Jong, P. T. V. M. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00580-7 · Cited by 1,071
Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .
Bressler, N. M. (2004) · JAMA · doi:10.1001/jama.291.15.1900 · Cited by 684
Age-Related Macular Degeneration
Fine, S. L., Berger, J. W., Maguire, M. G., & Ho, A. C. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420707 · Cited by 418
Incidence and progression rates of age-related maculopathy: the Rotterdam Study.
Klaver, C. C. W., Assink, J. J. M., van Leeuwen, R., Wolfs, R. C. W., Vingerling, J. R., Stijnen, T., Hofman, A., & de Jong, P. T. (2001) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 353
Cardiovascular Risk Factors and the Long-term Incidence of Age-Related Macular Degeneration
Tan, J. S. L., Mitchell, P., Smith, W., & Wang, J. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.09.033 · Cited by 238
Cardiovascular risk factors: when should we treat?
Tonkin, A. M., Lim, S. S., & Schirmer, H. (2003) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05092.x · Cited by 186
Research works printed but not linked: 3
- Soubrane, 2002, Presse Med, 31, 1282
- Klaver, 2001, Invest Ophthalmol Vis Sci, 42, 2237
- Smith, 2004, Br J Ophthalmol, 88, 107
Cited by
The economics of vision impairment and its leading causes: A systematic review
Marques, A. P., Ramke, J., Cairns, J., Butt, T., Zhang, J. H., Jones, I., Jovic, M., Nandakumar, A., Faal, H., Taylor, H., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101354 · Cited by 137
The burden of neovascular age-related macular degeneration: a patient’s perspective
Spooner, K., Mhlanga, C., Hong, T., Broadhead, G., & Chang, A. (2018) · Clinical ophthalmology · doi:10.2147/opth.s185052 · Cited by 125
“The burden on patients has been extensively researched, documenting the significant magnitude of medical and nonmedical costs among nAMD patients.(17,18) However, the precise costs that anti-VEGF therapies impose on caregivers remain poorly defined.”
Ferreira, A., Sagkriotis, A., Olson, M. S., Lu, J., Makin, C., & Milnes, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133968 · Cited by 59
“The economic burden associated with nAMD can therefore be considerable, reflecting both direct medical costs of diagnosis and treatment, and indirect costs associated with vision aids and care costs.[8,9] Current standard care for the treatment of nAMD includes anti-vascular endothelial growth factor (anti-VEGF) thera…”
BackgroundCost Effectiveness of Treatments for Wet Age-Related Macular Degeneration
Mitchell, P., Annemans, L., White, R., Gallagher, M., & Thomas, S. K. (2011) · PharmacoEconomics · doi:10.2165/11585520-000000000-00000 · Cited by 57
“Most clinical studies in wet AMD have evaluated amixture of first- and second-eye cases, reflective of clinical practice; the MICMAC observational study conducted in France, Germany and Italy showed that the use of laser photocoagulation and PDT was similar in first- and second-eye cases.([73]) The growing off-label u…”
ResultMatamoros, E., Maurel, F., Léon, N., Solomiac, A., Bardoulat, I., Joubert, M., Hermans, M., Moser, E., Le Picard, S., Souied, E. H., et al. (2015) · Ophthalmologica · doi:10.1159/000433448 · Cited by 40
Metadata
- Authors
- Bandello, F., Augustin, A., Sahel, J.-A., Benhaddi, H., Negrini, C., Hieke, K., & Berdeaux
- Affiliations
- University of Udine (IT)
- Conservatoire National des Arts et Métiers (FR)
- Corresponding author
- Berdeaux,, Gilles H
- Venue
- Drugs & Aging
- Published
- 2008
- Volume
- 25
- Issue
- 3
- Pages
- 255-268
- ISSN
- 1170-229X (ISSN-L)
- OpenAlex
- W2150815840
- Cited by
- 19
- References
- 48
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 1 · 2012: 2
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Funders
- Aeronautics Research Mission Directorate
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- neovascular age-related macular degeneration, visual acuity, health care costs, non-medical costs, disease severity, economic burden, cross-national comparison, France, Germany, Italy
- MeSH terms
- Aged, Analysis of Variance, Cross-Sectional Studies, Data Collection, Health Expenditures, Fees and Charges, Female, France, Germany, Home Care Services, Humans, Italy, Macular Degeneration, Male, Severity of Illness Index, Visual Acuity, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between Visual Acuity and Medical and Non-Medical Costs in Patients with Wet Age-Related Macular Degeneration in France, Germany and Italy. https://app.cochat.ai/papers/10.2165/00002512-200825030-00007
- The paper
- Bandello, F., Augustin, A., Sahel, J.-A., Benhaddi, H., Negrini, C., Hieke, K., & Berdeaux. (2008). Association between Visual Acuity and Medical and Non-Medical Costs in Patients with Wet Age-Related Macular Degeneration in France, Germany and Italy. Drugs & Aging. https://doi.org/10.2165/00002512-200825030-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.